STOCK TITAN

[Form 4] Verisk Analytics, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Negative)
Form Type
4

Verisk Analytics (VRSK) reporting person Elizabeth Mann, Chief Financial Officer and director, disclosed a sale of 300 shares of Verisk common stock on 09/16/2025 at a price of $254.72 per share. After the transaction Ms. Mann beneficially owned 15,165 shares directly. The filing notes the shares were sold pursuant to a pre-established 10b5-1 trading plan entered into on December 13, 2024, and the Form 4 was signed by an attorney-in-fact on 09/16/2025. The form reports a routine, single non-derivative sale by an executive.

Verisk Analytics (VRSK) osservara la persona informante Elizabeth Mann, Chief Financial Officer e membro del consiglio, ha comunicato la vendita di 300 azioni ordinarie Verisk il 16/09/2025 a un prezzo di $254,72 per azione. Dopo la transazione la signora Mann deteneva direttamente 15.165 azioni. Il modulo segnala che le azioni sono state vendute ai sensi di un pre-established 10b5-1 trading plan stipulato il 13 dicembre 2024, e il Form 4 è stato firmato da un procuratore-in-fact il 16/09/2025. Il modulo riporta una vendita ordinaria, unica e non derivativa, da parte di un dirigente.

Verisk Analytics (VRSK), la persona informante Elizabeth Mann, Directora Financiera y miembro del consejo, comunicó la venta de 300 acciones de Verisk common stock el 16/09/2025 a un precio de $254.72 por acción. Después de la transacción, la Sra. Mann poseía directamente 15.165 acciones. El archivo señala que las acciones se vendieron conforme a un plan de trading 10b5-1 preestablecido celebrado el 13 de diciembre de 2024, y el Form 4 fue firmado por un apoderado el 16/09/2025. El formulario informa de una venta rutinaria, única y no derivativa por parte de un ejecutivo.

Verisk Analytics (VRSK) 보고자 Elizabeth Mann, 최고재무책임자 겸 이사, Verisk 보통주 300주2025-09-16에 주당 $254.72에 매도했다고 공시했습니다. 거래 후 Mann 여사는 직접 15,165주를 보유하게 되었습니다. 서류에는 매도가 미리 정해진 10b5-1 트레이딩 플랜에 따라 2024년 12월 13일에 체결되었으며, Form 4는 2025-09-16에 대리인이 서명했습니다. 이 양식은 경영진의 일반적이고 단일 비파생 매도를 보고합니다.

Verisk Analytics (VRSK) la personne déclarante Elizabeth Mann, Directrice financière et administratrice, a divulgué la vente de 300 actions ordinaires Verisk, le 16/09/2025, à un prix de 254,72 $ par action. Après la transaction, Mme Mann détenait directement 15 165 actions. Le dossier indique que les actions ont été vendues conformément à un plan de trading 10b5-1 préétabli conclu le 13 décembre 2024, et le Formulaire 4 a été signé par un mandataire le 16/09/2025. Le formulaire rapporte une vente routinière, unique et non dérivée par un dirigeant.

Verisk Analytics (VRSK) meldende Person Elizabeth Mann, CFO und Direktorin, hat den Verkauf von 300 Verisk-Stammaktien am 16.09.2025 zu einem Preis von 254,72 $ pro Aktie bekannt gegeben. Nach der Transaktion besaß Frau Mann direkt 15.165 Aktien. Der Bericht vermerkt, dass die Aktien gemäß einem vorab festgelegten 10b5-1-Handelsplan verkauft wurden, der am 13. Dezember 2024 abgeschlossen wurde, und das Form 4 von einem Bevollmächtigten am 16.09.2025 unterzeichnet wurde. Das Formular meldet einen routinemäßigen, einzelnen nicht derivativen Verkauf durch einen Führungskräfte.

Verisk Analytics (VRSK) الشخص المُبلِّغ إليهم Elizabeth Mann، المدير المالي والمدير، أفادت ببيع 300 سهماً من أسهم Verisk العادية في 16/09/2025 بسعر $254.72 للسهم الواحد. بعد الصفقة امتلكت السيدة مان 15,165 سهماً بشكل مباشر. تشير الإيجاز إلى أن الأسهم بِيعت وفقاً لخطة تداول 10b5-1 محددة سلفاً أُبرمت في 13 ديسمبر 2024، وتم توقيع النموذج Form 4 من قبل وكيل مفوَّض في 16/09/2025. يُبلِغ النموذج عن بيع روتيني واحد غير مشتق من قِبل مسؤول تنفيذي.

Verisk Analytics (VRSK) 报告人 Elizabeth Mann,首席财务官兼董事,披露于 2025-09-16 以每股 $254.72 的价格出售 300 股 Verisk 普通股。交易后,Mann 女士直接持有 15,165 股。 filing 指出股票的出售符合于事先设定的 10b5-1 交易计划,该计划于 2024 年 12 月 13 日 签订,Form 4 于 2025-09-16 由授权代理人签署。该表格报告了一次常规、单一且非派生的出售行为。

Positive
  • None.
Negative
  • Insider sale of 300 shares disclosed, reducing direct holdings to 15,165 shares (sale price $254.72)

Insights

TL;DR: A small, routine insider sale under a pre-established 10b5-1 plan; not a material change to ownership.

The sale of 300 shares at $254.72 represents a modest disposition relative to the reported post-transaction holding of 15,165 shares. Because the trade was executed under a 10b5-1 plan established on December 13, 2024, it follows a pre-authorized schedule and reduces the likelihood that the sale was based on undisclosed, material information. For investors, this appears to be routine liquidity by an executive rather than a signal of changing firm fundamentals.

TL;DR: Compliance looks appropriate—transaction disclosed on Form 4 and tied to a documented 10b5-1 plan.

The filing meets Section 16 reporting requirements: it lists the reporting person, relationship to the issuer, transaction details, and an explanation that the sale was made pursuant to a 10b5-1 plan. The presence of an attorney-in-fact signature is documented. From a governance perspective, documented pre-clearance via a 10b5-1 plan and timely Form 4 reporting align with standard insider trading controls.

Verisk Analytics (VRSK) osservara la persona informante Elizabeth Mann, Chief Financial Officer e membro del consiglio, ha comunicato la vendita di 300 azioni ordinarie Verisk il 16/09/2025 a un prezzo di $254,72 per azione. Dopo la transazione la signora Mann deteneva direttamente 15.165 azioni. Il modulo segnala che le azioni sono state vendute ai sensi di un pre-established 10b5-1 trading plan stipulato il 13 dicembre 2024, e il Form 4 è stato firmato da un procuratore-in-fact il 16/09/2025. Il modulo riporta una vendita ordinaria, unica e non derivativa, da parte di un dirigente.

Verisk Analytics (VRSK), la persona informante Elizabeth Mann, Directora Financiera y miembro del consejo, comunicó la venta de 300 acciones de Verisk common stock el 16/09/2025 a un precio de $254.72 por acción. Después de la transacción, la Sra. Mann poseía directamente 15.165 acciones. El archivo señala que las acciones se vendieron conforme a un plan de trading 10b5-1 preestablecido celebrado el 13 de diciembre de 2024, y el Form 4 fue firmado por un apoderado el 16/09/2025. El formulario informa de una venta rutinaria, única y no derivativa por parte de un ejecutivo.

Verisk Analytics (VRSK) 보고자 Elizabeth Mann, 최고재무책임자 겸 이사, Verisk 보통주 300주2025-09-16에 주당 $254.72에 매도했다고 공시했습니다. 거래 후 Mann 여사는 직접 15,165주를 보유하게 되었습니다. 서류에는 매도가 미리 정해진 10b5-1 트레이딩 플랜에 따라 2024년 12월 13일에 체결되었으며, Form 4는 2025-09-16에 대리인이 서명했습니다. 이 양식은 경영진의 일반적이고 단일 비파생 매도를 보고합니다.

Verisk Analytics (VRSK) la personne déclarante Elizabeth Mann, Directrice financière et administratrice, a divulgué la vente de 300 actions ordinaires Verisk, le 16/09/2025, à un prix de 254,72 $ par action. Après la transaction, Mme Mann détenait directement 15 165 actions. Le dossier indique que les actions ont été vendues conformément à un plan de trading 10b5-1 préétabli conclu le 13 décembre 2024, et le Formulaire 4 a été signé par un mandataire le 16/09/2025. Le formulaire rapporte une vente routinière, unique et non dérivée par un dirigeant.

Verisk Analytics (VRSK) meldende Person Elizabeth Mann, CFO und Direktorin, hat den Verkauf von 300 Verisk-Stammaktien am 16.09.2025 zu einem Preis von 254,72 $ pro Aktie bekannt gegeben. Nach der Transaktion besaß Frau Mann direkt 15.165 Aktien. Der Bericht vermerkt, dass die Aktien gemäß einem vorab festgelegten 10b5-1-Handelsplan verkauft wurden, der am 13. Dezember 2024 abgeschlossen wurde, und das Form 4 von einem Bevollmächtigten am 16.09.2025 unterzeichnet wurde. Das Formular meldet einen routinemäßigen, einzelnen nicht derivativen Verkauf durch einen Führungskräfte.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Mann Elizabeth

(Last) (First) (Middle)
C/O VERISK ANALYTICS, INC.
545 WASHINGTON BOULEVARD

(Street)
JERSEY CITY NJ 07310

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Verisk Analytics, Inc. [ VRSK ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Financial Officer
3. Date of Earliest Transaction (Month/Day/Year)
09/16/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 09/16/2025 S 300(1) D $254.72 15,165 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. These shares were sold pursuant to a 10b5-1 plan that Ms. Mann entered into on December 13, 2024.
/s/ Kathy Card Beckles, Attorney-in-fact 09/16/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Elizabeth Mann (VRSK) disclose on Form 4?

She disclosed a sale of 300 shares of Verisk common stock on 09/16/2025 at $254.72 per share.

How many Verisk shares does Elizabeth Mann own after the sale?

The filing reports she beneficially owned 15,165 shares following the reported transaction.

Was the sale part of a 10b5-1 plan for VRSK insider trades?

Yes. The filing states the shares were sold pursuant to a 10b5-1 plan entered on December 13, 2024.

Who signed the Form 4 for the reporting person?

The Form 4 was signed by Kathy Card Beckles, Attorney-in-fact on 09/16/2025.

Does the Form 4 show any derivative transactions for Elizabeth Mann?

No. Table II (derivative securities) contains no reported transactions; only a non-derivative sale is reported.
Verisk Analytics

NASDAQ:VRSK

VRSK Rankings

VRSK Latest News

VRSK Latest SEC Filings

VRSK Stock Data

33.94B
139.36M
0.25%
95.82%
1.92%
Consulting Services
Services-computer Processing & Data Preparation
Link
United States
JERSEY CITY